Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, PR China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Diseases, Beijing, PR China.
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, PR China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Diseases, Beijing, PR China; Peking-Tsinghua Center for Life Sciences, Beijing, PR China.
Transpl Immunol. 2023 Jun;78:101830. doi: 10.1016/j.trim.2023.101830. Epub 2023 Mar 25.
Cytokine storm development is a major cause of many transplant-related complications, especially during the conditioning regimen. This study aimed to characterize the cytokine profile and determine its prognostic impact during conditioning in patients undergoing subsequent haploidentical stem cell transplantation. A total of 43 patients were enrolled in this study. Sixteen cytokines associated with cytokine release syndrome (CRS) during anti-thymocyte globulin (ATG) treatment were quantified in patients undergoing haploidentical stem cell transplantation. Thirty-six (83.7%) patients developed CRS during ATG treatment; most of those cases (33/36; 91.7%) were classified as grade 1 CRS, whereas only three (7.0%) developed grade 2 CRS. CRS was observed more frequently on the first (15/43; 34.9%) and second day (30/43; 69.8%) of ATG infusion. No factors were identified that could predict the development of CRS on the first day of ATG treatment. Five of the 16 cytokines (interleukins 6, 8, and 10 (IL-6, IL-8, and IL-10), C-reactive protein (CRP), and procalcitonin (PCT)) were significantly elevated during ATG treatment, although only the level of IL-6, IL-10, and PCT were associated with the severity of CRS. However, neither CRS nor the cytokine levels significantly impacted the development of acute graft-versus-host disease (GVHD) or cytomegalovirus (CMV) infection or affected overall survival.
细胞因子风暴的发展是许多移植相关并发症的主要原因,尤其是在预处理期间。本研究旨在描述接受单倍体造血干细胞移植患者预处理期间细胞因子特征,并确定其对预后的影响。本研究共纳入 43 例患者。对接受单倍体造血干细胞移植的患者进行抗胸腺细胞球蛋白(ATG)治疗期间与细胞因子释放综合征(CRS)相关的 16 种细胞因子进行定量检测。36 例(83.7%)患者在 ATG 治疗期间发生 CRS;其中大多数(33/36;91.7%)为 1 级 CRS,仅 3 例(7.0%)为 2 级 CRS。CRS 更常见于 ATG 输注的第 1 天(15/43;34.9%)和第 2 天(30/43;69.8%)。没有发现任何因素可以预测 ATG 治疗第 1 天 CRS 的发生。在 ATG 治疗期间,有 5 种细胞因子(白细胞介素 6、8 和 10(IL-6、IL-8 和 IL-10)、C 反应蛋白(CRP)和降钙素原(PCT))显著升高,尽管只有 IL-6、IL-10 和 PCT 水平与 CRS 的严重程度相关。然而,无论是 CRS 还是细胞因子水平均未显著影响急性移植物抗宿主病(GVHD)或巨细胞病毒(CMV)感染的发生,也未影响总生存率。